Kornimate/medical-research-clean huggingface dataset:
the relationship of phthalate exposure during pregnancy and preeclampsia

Conditions: Phthalate Exposure; Preeclampsia; Estrogen; Progestin

Summary: phthalates are a group of ubiquitous synthetic endocrine-disrupting chemicals. fetal and neonatal periods are particularly susceptible to endocrine disorders, which prenatal exposure to phthalates causes. there is increasing evidence concerning the potential endocrine disrupting for phthalate exposure during pregnancy. prenatal exposure phthalates would disrupt the level of sex hormone in pregnant women, which results in preeclampsia. the relationship of prenatal phthalate exposure with maternal and neonatal outcomes in human beings was often sex-specific associations. because of the potentially harmful influence of prenatal phthalate exposure, steps should be taken to prevent or reduce phthalate exposure during pregnancy.


Eligibility criteria:
inclusion criteria: * singleton pregnancy * term pregnancy with the gestational age of 37-40 weeks exclusion criteria: * maternal systemic diseases (hypertension disorders, immunological diseases) or pregnant complications (polyhydramnios, oligohydramnios, diabetes mellitus, intrahepatic cholestasis of pregnancy) * delivery before 37 weeks or after 40 weeks
s8600-s9031-s9333-a, study of dna in samples from patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients respond to treatment. purpose: this research trial studies dna in samples from patients with acute myeloid leukemia.

objectives: * to identify differentially methylated regions (dmrs) associated with overall survival (os) of acute myeloid leukemia (aml) patients with normal cytogenetics. * to develop and evaluate in an independent validation set a prognostic score for os based on the identified dmr. * to determine whether the prognostic score can group patients into risk groups based on os. outline: archived blood or bone marrow samples are analyzed for dna methylation alterations by charm array-based genome assay. each patient's clinical data is also collected.

Eligibility criteria:
disease characteristics: * de novo acute myeloid leukemia (aml) patients with normal cytogenetics treated with curative therapy who survived at least 28 days after therapy started * samples will be taken from the following studies: swog-8600, swog-9031, swog-9333, swog-9500, swog-s9918, swog-s0106, and swog-s0112 * blood or marrow specimens can be used patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: untreated adult acute myeloid leukemia
study of cm310 in adolescent subjects with atopic dermatis

Conditions: Atopic Dermatitis

Summary: this is a multi-center, single arm, open label phase 3 study to evaluate the safety and efficacy of cm310 in children patients with moderate-to-severe atopic dermatitis.


Eligibility criteria:
inclusion criteria: * have the ability to understand the study and voluntarily sign a written informed consent form (icf). * subjects who must complete the evaluation of week 18 of the main study. * with atopic dermatitis. exclusion criteria: * any major surgery planned during the research period. * subjects with potential fertility do not agree to adopt efficient contraceptive measures throughout the entire study period; pregnant or breastfeeding women, or women planning to conceive or breastfeed during the study period. * with any circumstance that the subject is not suitable to participate in this study.
continuous glucose monitoring in neonatal hyperinsulinism

Conditions: Hyperinsulinism; Hypoglycemia Neonatal

Summary: the investigators are studying the accuracy of dexcom g6 continuous glucose monitors placed on babies with hyperinsulinism in the miller children's hospital neonatal intensive care unit. the participants will wear the device for 10 days on their lateral thigh. whenever blood sugars are checked by glucometer, the investigators will also record the continuous glucose monitor sugar. additionally, if the continuous glucose monitor alarms for a low sugar or an impending low sugar, the investigators will check the blood sugar by glucometer and, if verified to be low, treat the low blood sugar accordingly.


Eligibility criteria:
inclusion criteria: * age: 0-90 days old * gestational age: \> 28 weeks gestational age * diagnosis of hyperinsulinism based on critical sample and/or glucagon challenge exclusion criteria: * diffuse skin disease such that placement of a dexcom g6 sensor would be difficult to secure * infants colonized or infected with multi-drug resistant organisms (i.e. mrsa, vre, esbl producing bacteria) * infants on hypothermic protocols * infants expected to remain in the nicu \<24 hours * infants enrolled in a competing clinical trial * family/team have decided to limit or redirect from aggressive nicu technological support * ward of the state
assessment of cryobeauty mains et decollete versus liquid nitrogen cryotherapy, in the treatment of solar lentigines

Conditions: Solar Lentigo

Summary: this study evaluates the performance of new technology "cryotherapy mains et decollete" against a classic cryotherapy "nitrogen liquid " to treat solar lentigines. the hands and the neckline will be randomised, either left or right side and treated by two cryotherapy devices: 1. cryotherapy mains et decollete is the device under evaluation. 2. liquid nitrogen is a comparator device.


Eligibility criteria:
inclusion criteria: * phototype ii to iv * presenting solar lentigos on both hands and neck, diameter ≤ 6mm * accepting not to expose the body to sunlight or artificial uv rays during the study * affiliate to a health insurance plan * having undergone a general clinical examination attesting to his / her ability to participate in the study * having given written consent exclusion criteria: * having carried out aesthetic care (exfoliants, scrubs or self-tanning, manicure, hand care, uv ...) in the month before the start of the study, at the level of the hands and/or neckline. * having applied a depigmenting product in the month preceding the start of the study, at the level of the hands and/or neckline. * having carried out aesthetic care at a dermatologist (laser, ipl, peeling, depigmenting creams, cryotherapy ...), at the level of the hands and/or neckline, during the last six months * dermatosis, autoimmune disease (vitiligo), systemic, chronic or acute disease, or any other disease that may interfere with the treatment or influence the results of the study (people with diabetes, circulatory problems, cold allergies, with raynaud's syndrome ...) * receiving general or local treatment (corticosteroids ...) likely to interfere with the evaluation of the studied parameters. * participating in another study or being in an exclusion period from a previous study * being incapable of following the requirements of the protocol * person protected by law * unable to read and write french * pregnant woman or woman wishing to be pregnant during the study, or during breastfeeding period * women of childbearing age who do not have contraception
clonicel (clonidine sustained release) as add-on to stimulant medication in 6 to 17 yr-olds with adhd

Conditions: ADHD

Summary: the purpose of this study is to determine if clonicel (clonidine hcl sustained release) is a safe and effective add-on to psychostimulant therapy in children and adolescents with attention deficit hyperactivity disorder (adhd).


Eligibility criteria:
inclusion criteria: * age 6-17 years, inclusive * diagnosis of adhd * currently on a stable psychostimulant regimen for adhd * lack of adequate response to stable psychostimulant regimen * ability to swallow tablets exclusion criteria: * clinically significant illnesses or abnormalities upon evaluation * conduct disorder * intolerance to clonidine * history of seizures or syncope

Keywords: adhd add attention deficit hyperactivity disorder attention deficit clonidine clonicel addrenex
a phasei/iia study to determine the safety and tolerability of ma09-hrpe cells in patients with advanced dry amd

Conditions: Dry Age Related Macular Degeneration

Summary: to evaluate the safety and tolerability of ma09-hrpe cellular therapy in patients with advanced dry amd to evaluate the safety of the surgical procedures when used to implant ma09-hrpe cells to assess the number of hrpe cells to be transplanted in future studies to evaluate on an exploratory basis potential efficacy endpoints to be used in future studies of ma09-hrpe cellular therapy.


Eligibility criteria:
inclusion criteria: * adult male or female over 55 years of age. patient should be in sufficiently good health to reasonably expect survival for at least four years after treatment * clinical findings consistent with advanced dry amd * ga defined as attenuation or loss of rpe as observed by biomicroscopy, oct, and fa. * no evidence of current or prior choroidal neovascularization in the treated eye * the visual acuity (bcva) of the eye to receive the transplant found to be eligible for trial based on study protocol * electrophysiological findings consistent with advanced dry amd. * medically suitable to undergo vitrectomy and subretinal injection. * medically suitable for general anesthesia or waking sedation, if needed. * medically suitable for transplantation of an embryonic stem cell line exclusion criteria: * presence of active or inactive cnv in the eye to be treated. * presence or history of retinal dystrophy, retinitis pigmentosa, chorioretinitis, central serious choroidopathy, diabetic retinopathy or other retinal vascular or degenerative disease other than armd. * history of optic neuropathy. * macular atrophy due to causes other than amd. * presence of glaucomatous optic neuropathy in the study eye, uncontrolled iop, or use of two or more agents to control iop (acetazolamide, beta blocker, alpha-1-agonist, prostaglandins, anhydrous carbonic inhibitors) * cataract of sufficient severity likely to necessitate surgical extraction within 1 year. * history of retinal detachment repair in the study eye. * history of myocardial infarction in previous 12 months. * history of diabetes mellitus. * history of cognitive impairments or dementia which may impact the patients ability participate in the informed consent process and to appropriately complete evaluations. * any immunodeficiency. * any abnormalities in laboratory test result. * serologic evidence of infection with hepatitis b, hepatitis c, or hiv. * current participation in any other clinical trial. * participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration. * any other sight-threatening ocular disease. * ocular lens removal within previous 3 months. * ocular surgery in the study eye in the previous 3 months * if female, pregnancy or lactation. * any other medical condition, which, in the investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromises patient safety, or interferes with the interpretation of the study results.
teaching first aid and trauma management to school students

Conditions: Trauma-related Wound; Head Injury; Choking; Nose Bleed; Child, Only; Emergencies

Summary: this proposal aims to describe research that will utilize first aid in primary education students and will attempt to identify the frequency with which the training should be repeated and the type of trainer who will carry out the training program.

the training concerns courses with theoretical knowledge and practical skills related to first aid. taking into account children's cognitive and psychological development, students will be trained in the following topics: calling an ambulance, managing bleeding, handling an unconscious patient, drowning, and managing a head injury. classroom teachers and specialized staff will teach classes. the evaluation of knowledge and skills will be done with a questionnaire. the evaluation will take place before and immediately after the training, two months and seven months after the training.

Eligibility criteria:
inclusion criteria: * students at primary schools and kindergarten, 4-9 years old exclusion criteria: * students over 9 years old

Keywords: first aid training, children
iloperidone augmentation of ssris for patients with major depressive disorder with residual anger and irritability

Conditions: Major Depressive Disorder

Summary: iloperidone is an atypical antipsychotic drug, fda-approved for the acute treatment of schizophrenia in adults in 2009 (marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating symptoms like anger and anxiety (fava et al., 1997; wang et al., 2010). the investigators therefore feel that an adequately sized, well powered, double-blind, placebo-controlled, randomized, cross-over study of iloperidone augmentation of ssris among mdd outpatients in partial remission with residual anger and irritability is warranted at this point to evaluate its efficacy, safety and tolerability on residual anger, irritability and depressive symptoms. main hypothesis: adults with mdd in partial remission, who are experiencing residual symptoms of anger and irritability, assigned to treatment with iloperidone will demonstrate a significantly greater reduction in the total score of the anger/hostility scale of the symptom questionnaire from baseline to endpoint than those assigned to placebo using the cross-over design.


Eligibility criteria:
inclusion criteria: * written informed consent. * men or women ages 18-65 years old. * current major depressive episode in partial remission based on the structured clinical interview for dsm iv-axis i disorders (scid i/p) and a ham-d-17 score between 9 and 15. * current treatment with a selective serotonin reuptake inhibitor (ssri) other than paroxetine or fluoxetine for at least three months, at a stable dose for the past 4 weeks, and more than 50% but less than 75% improvement on the current antidepressant, as determined by the mgh antidepressant treatment response questionnaire (atrq). * score \> 8 on the anger/hostility scale of the symptom questionnaire both at screen and baseline. exclusion criteria: * the following dsm-iv diagnoses: 1) organic mental disorders; 2) substance use disorders, including alcohol, active within the last 3 months; 3) schizophrenia; 4) delusional disorder; 5) psychotic disorders not elsewhere classified; 6) bipolar disorder; and 9) antisocial personality disorder; 10) dementia. * current, serious suicidal or homicidal risk. * pregnancy or breast-feeding. * serious, unstable medical illness including cardiovascular, kidney, liver, neurological and endocrine disorders. * congenital long qt syndrome or a qtc \> 450 ms. * history of cardiac arrhythmias. * electroconvulsive therapy (ect) within the 6 months preceding baseline. * concomitant use of buspirone, fluoxetine, paroxetine, any psychostimulant, modafinil, other antipsychotic drugs, or anticonvulsants (although stable doses of benzodiazepines and hypnotics are allowed) (see concomitant therapy).
post approval commitment study

Conditions: Dupuytren's Contracture

Summary: an agreement has been made to conduct a post-approval commitment study that provides supplementary information relating to the use of xiapex® as well as other non-pharmacological treatments for dupuytren's contracture by health care professionals in a real world clinical setting.

phase 4, open label, multi-center, prospective non-interventional descriptive

Eligibility criteria:
inclusion criteria: * adults with a palpable cord eligible for the treatment of dupuytren's contracture exclusion criteria: none

Keywords: 'dupuytren's contracture' 'xiapex' 'surgery'
carpal tunnel syndrome in patients with psoriatic arthritis

Conditions: Carpal Tunnel Syndrome; Psoriatic Arthritis

Summary: this study aimed to investigate median nerve hypervasculatitation in psoriatic arthritis (psa) patients with cts or without cts by using smi, then compare them with normal people.

carpal tunnel syndrome(cts), a type of median nerve neuropathies, is the most common peripheral nerve entrapment syndrome. most cases are idiopathic but cts can be associated with rheumatologic disorders. there isn't any gold standard technique in diagnosis of cts. electrodiagnostic studies (eds) are usually performed to confirm diagnose, to differentiate other diseases or to detect severity. but eds have some disadvantages such as eds are time consuming, uncomfortable, may require interventional procedures, can not directly assess the anatomy of the median nerve and its surrounding structures. for these reasons, the use of ultrasonography (us) in the diagnosis of carpal tunnel syndrome has been investigated for a long time. most of them focused on the cross-sectional area(csa) of median nerve. fewer studies have investigated the vascularity of the median nerve. but there is conflict results because conventional doppler techniques may fail to show small vessels or slow blood flow. superb microvascular imaging (smi) is a new ultrasound technology that can diferentiate blood flow signals from artifacts by using a new algorithm. in carpal tunnel syndrome hypervasularitation of median nerve has showed by smi. to our best knowledge, there isn't any study assessing median nerve hypervascularity by using smi in psa. so we aimed to investigate median nerve hypervasculatitation in psoriatic arthritis (psa) patients with cts or without cts by using smi, then compare them with normal people.

Eligibility criteria:
inclusion criteria: * psa patients according to the caspar criteria who consecutively applied to the ftr outpatient clinic for psa follow-up and healthy volunteers who applied to the ftr outpatient clinic enrolled in the study. exclusion criteria: * patients were not included in the study if they had a history of wrist or hand fracture, surgery, neurologic disorders such as radiculopathy, polyneuropathy or cerebrovas-cular disease, a history of conditions associated with an increased incidence of cts such as diabetes mellitus, pregnancy, hypothyroidism or severe systemic diseases.

Keywords: carpal tunnel syndrome psoriatic arthritis superb microvascular imaging
respiratory weaning following cardiac surgery.

Conditions: Respiratory Insufficiency

Summary: respiratory weaning failure worsens prognostic of patients following on-pump cardiac surgery. there are increasing evidences that pulmonary, diaphragmatic or cardiologic echographies are useful in order to improve this critical medical status. based both on a previous study conducted in the critical care unit of purpan and on literature we hypothesize that a combined thoracic echography score could be of interest. we make the hypothesis that the use of a score based on thoracic combined echography (etc = cardiac, pulmonary and diaphragmatic) allows to predict the failure of respiratory weaning in cardiac surgery and allows to improve the characterization of the causes of this failure


Eligibility criteria:
inclusion criteria: * adult (\> 18 years old) beneficiating of mechanical ventilation following cardiac surgery * weaning test period * patient insured under the french social security system exclusion criteria: * tracheostomy * neurological disorders * need for prophylactic non invasive ventilation. * global obstructive lung disease with a forced expiratory volume \< 50%. * judicial protection * patient already included in a trial still running. * pregnancy

Keywords: respiratory weaning pulmonary ventilation
assessing outcomes in ed patients with rv failure

Conditions: Right Heart Failure

Summary: millions of americans seek emergency care for acute shortness of breath, and many undergo computerized tomographic pulmonary angiography (ctpa) testing that is negative for acute disease. management of patients with persistent shortness of breath despite normal testing continues to pose a challenge for clinicians. right ventricular (rv) failure is a common cause of dyspnea that brings patients to the emergency department (ed), however, it is often not considered in the differential diagnosis, remains unrecognized, or patients are not properly followed up once diagnosed. delays in diagnosis and management of rv failure are associated with poor outcomes. the investigators propose a novel clinical pathway, which entails identifying and enrolling patients with rv failure in the ed, then referring them to a specialized cardiovascular clinic where they will receive a standardized evaluation and management plan. our hypothesis is that management of rv failure, through this pathway, will improve patient outcomes when compared to standard care. the primary outcome will assess 1-year unscheduled healthcare visits.


Eligibility criteria:
inclusion criteria: * adult patients \> 18 years old, * with a non-significant ctpa scan (i.e. no acute disease), dyspnea plus an emergency physician performed echocardiogram with isolated rv failure or ctpa scan with evidence of pulmonary hypertension or comprehensive echocardiogram within 3 months of index hospital visit showing isolated rv dysfunction exclusion criteria: * currently being evaluated and/or treated for rv failure or ph, * those unable to have a comprehensive echocardiography performed, * those with indeterminate rv function or lv dysfunction on comprehensive echocardiography, and * those patients with circumstances where they may be lost to follow-up (homeless, prisoner, severe psychiatric disorder, no reliable contact information).
safety profile of secotex ® in patients with benign prostatic hyperplasia

Conditions: Prostatic Hyperplasia

Summary: the objective of this study is to conduct a prescription event monitoring (pem) involving patients treated with secotex® (tamsulosin) in "real life" settings. the aim of a pem is to monitor the safety profile of secotex® in a cohort of patients with benign prostatic hyperplasia as used in general practice


Eligibility criteria:
inclusion criteria: * patients of any age with a diagnosis of symptomatic benign prostatic hyperplasia (bph) and/or that, according to the physician, their symptoms require medical treatment to improve their quality of life. the patients could be naïve to treatment or could be on treatment with other drugs but have not responded adequately to treatment. this study is non-interventional, so the decision to treat must be based on the best standard accepted clinical practice, and according to secotex® prescribing information exclusion criteria: * patients with known hypersensitivity to tamsulosin, or any other component of the product * patients with a history of orthostatic hypotension or severe liver failure